Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

Patients with highly active relapsing-remitting multiple sclerosis (RRMS) are at greater risk for disease progression and may respond differently to MS therapeutics than those with less active disease. The current post hoc analysis evaluated the effects of daclizumab high-yield process (DAC HYP) vs....

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Giovannoni, Gavin, Radue, Ernst-Wilhelm, Havrdova, Eva, Riester, Katherine, Greenberg, Steven, Mehta, Lahar, Elkins, Jacob
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2013
Témata:
Original Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3915085/
https://ncbi.nlm.nih.gov/pubmed/24375015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-013-7196-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky